Concord Biotech Limited (CONCORDBIO) — Financial Results | 27 June 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Concord Biotech Limited announced that its trading window for equity shares will close on July 1, 2026, and remain shut until 48 hours after the unaudited financial results for the quarter ended June 30, 2026 are declared, as mandated by SEBI insider trading regulations.

📄 View Original Announcement (PDF)

About Concord Biotech Limited (CONCORDBIO)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹15,212.77 Cr P/E: 55.7 ROE: 13.5% ROCE: 18.1% Div Yield: 0.52%

View full CONCORDBIO stock details →

📡 Get AI alerts when CONCORDBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CONCORDBIO — Free

📊 More CONCORDBIO filings

See all CONCORDBIO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CONCORDBIO files new disclosures

Track CONCORDBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CONCORDBIO — Free

Free account · 2 AI queries/day